Fulgent Genetics, Inc.
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
About
CEO
Mr. Ming Hsieh
Employees
1,184
Instrument type
Common Stock
Sector
Healthcare
Industry
Diagnostics & Research
MIC code
XNMS
Address
4399 Santa Anita Avenue, El Monte, CA 91731, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | — | — | — | — |
| Jul 31, 2025 | — | — | — | — |
| May 1, 2025 | — | — | — | — |
| Feb 26, 2025 | -0.31 | — | — | — |
| Nov 8, 2024 | -0.15 | 0.31 | 0.46 | -306.67% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 3 |
| Average estimate | — | -0.13 | — | -0.46 |
| Low estimate | — | -0.21 | — | -0.66 |
| High estimate | — | -0.05 | — | -0.28 |
| Last year EPS | — | -0.01 | — | -0.16 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-231.790%
Next qtr. (Mar 2025)
-1,175.800%
Current year
60.520%
Next year (Dec 2025)
-186.600%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M |
| Cost of revenue | 184.76M | 252.07M | 215.53M | 89.81M | 14.11M |
| Gross profit | 104.46M | 366.90M | 777.05M | 331.91M | 18.42M |
| Operating expense | |||||
| Research & development | 41.44M | 28.91M | 24.22M | 11.58M | 6.54M |
| Selling general and admin | 130.47M | 149.99M | 75.17M | 30.17M | 12.31M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -75.30M | 181.50M | 675.95M | 290.16M | -428,000 |
| Non operating interest income | |||||
| Income | 21.44M | 5.50M | 1.35M | 1.53M | 837,000 |
| Expense | — | — | — | — | — |
| Other income expense | -120.23M | -2.98M | — | — | — |
| Pretax income | -174.09M | 184.03M | 677.30M | 291.68M | 409,000 |
| Tax provision | 1.15M | 42.10M | 174.80M | 72.53M | 43,000 |
| Net income | -175.24M | 141.92M | 506.24M | 214.31M | -411,000 |
| Basic EPS | -5.63 | 4.76 | 17.25 | 9.44 | -0.02 |
| Diluted EPS | -5.63 | 4.63 | 16.38 | 8.91 | -0.02 |
| Basic average shares | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M |
| Diluted average shares | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M |
| EBITDA | 71.08M | 217.14M | 686.96M | 293.12M | 1.68M |
| Net income from continuing op. | -175.24M | 141.92M | 506.24M | 214.31M | -411,000 |
| Minority interests | 7.41M | 1.48M | 1.13M | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.24B | 1.39B | 1.28B | 700.46M | 88.76M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 97.47M | 79.51M | 164.89M | 87.43M | 11.97M |
| Other short term investments | 326.68M | 446.73M | 285.61M | 211.94M | 16.30M |
| Accounts receivable | 51.13M | 52.75M | 138.91M | 183.86M | 6.56M |
| Other receivables | 1.32M | 19.84M | 1.64M | 19.19M | 166,000 |
| Inventory | 5.83M | 4.28M | 12.21M | 16.49M | 277,000 |
| Prepaid assets | 20.42M | 22.25M | 5.96M | 3.70M | 1.33M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | 277,000 |
| Non current assets | |||||
| Properties | 71.15M | 66.42M | 42.69M | 22.95M | 10.61M |
| Land and improvements | 9.70M | 8.40M | 7.90M | 7.90M | — |
| Machinery furniture equipment | 25.49M | 25.41M | 16.65M | 11.25M | 2.48M |
| Construction in progress | — | — | — | — | — |
| Leases | 11.22M | 11.80M | 4.00M | 1.58M | 876,000 |
| Accumulated depreciation | -51.63M | -43.28M | -19.63M | -10.92M | -7.99M |
| Goodwill | 187.16M | 436.70M | 137.71M | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 143.05M | 150.64M | 35.91M | — | — |
| Investments and advances | 444.01M | 339.03M | 507.01M | 132.50M | 42.82M |
| Other non current assets | 34.90M | 44.12M | 10.65M | 4.14M | 251,000 |
| Total liabilities | 102.04M | 116.18M | 112.84M | 131.07M | 5.98M |
| Current liabilities | |||||
| Accounts payable | 15.36M | 23.09M | 20.49M | 26.49M | 1.58M |
| Accrued expenses | 26.78M | 18.85M | 17.69M | 8.45M | 1.33M |
| Short term debt | 5.14M | 26.77M | 21.28M | 15.02M | 420,000 |
| Deferred revenue | 25.57M | 14.09M | 34.38M | 26.76M | 365,000 |
| Tax payable | — | — | 787,000 | 53.32M | 24,000 |
| Pensions | — | — | — | — | — |
| Other current liabilities | 164,000 | 5.30M | 10.68M | 82,000 | — |
| Non current liabilities | |||||
| Long term debt | 10.11M | 12.17M | — | 568,000 | 2.26M |
| Provision for risks and charges | — | — | — | 377,000 | — |
| Deferred liabilities | 7.96M | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 10.95M | 15.90M | 7.53M | 959,000 | — |
| Shareholders equity | |||||
| Common stock | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 |
| Retained earnings | 633.18M | 801.00M | 657.60M | 150.88M | -63.43M |
| Other shareholders equity | 1.21M | -20.90M | -759,000 | 438,000 | 146,000 |
| Total shareholders equity | 1.13B | 1.27B | 1.17B | 569.39M | 82.78M |
| Additional paid in capital | 501.72M | 486.59M | 501.91M | 418.07M | 146.06M |
| Treasury stock | — | — | — | — | — |
| Minority interest | -2.82M | 3.19M | 7.13M | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -175.24M | 141.92M | 506.24M | 214.31M | -411,000 | -5.61M | -2.51M | -5.39M | -4.99M | -990,000 |
| Depreciation | 26.14M | 32.66M | 11.00M | 2.96M | 2.11M | 2.16M | 1.73M | 1.17M | 575,000 | 196,000 |
| Deferred Taxes | 7.61M | 831,000 | -7.84M | -1.40M | -21,000 | 36,000 | -336,000 | 246,000 | — | — |
| Stock-Based Compensation | 42.92M | 32.64M | 15.88M | 8.16M | 3.21M | 2.30M | 2.12M | 4.65M | 8.16M | — |
| Other Non-Cash Items | 6.39M | 4.90M | 1.14M | 417,000 | 465,000 | 44,000 | -15,000 | 5.47M | — | — |
| Accounts Receivable | 2.39M | 68.64M | 42.30M | -178.48M | -839,000 | -1.97M | 214,000 | -2.32M | -1.78M | -416,000 |
| Accounts Payable | -6.90M | -25.34M | -12.21M | 22.62M | -329,000 | 102,000 | -363,000 | 1.09M | 132,000 | 150,000 |
| Other Assets & Liabilities | -6.86M | -9.17M | 6.68M | -21.54M | -35,000 | 91,000 | -1.54M | -381,000 | -163,000 | -138,000 |
| Operating Cash Flow | -103.54M | 247.09M | 563.20M | 47.05M | 4.15M | -2.84M | -702,000 | 4.55M | 1.94M | -1.20M |
| Investing Activities | ||||||||||
| Capital Expenditures | -21.43M | -28.36M | -23.75M | -35.12M | -1.18M | -2.83M | -5.36M | -3.78M | -2.03M | -731,000 |
| Net Intangibles | — | — | -32,000 | — | — | — | — | — | — | — |
| Net Acquisitions | -399,000 | -172.68M | -61.87M | -3.97M | -137,000 | — | — | — | — | — |
| Purchase of Investments | -491.91M | -432.98M | -730.49M | -324.36M | -52.08M | -24.19M | -11.66M | -39.02M | — | — |
| Sale of Investments | 552.64M | 372.71M | 269.59M | 37.01M | 24.35M | 27.97M | 14.97M | — | — | — |
| Investing Cash Flow | 38.90M | -261.31M | -546.52M | -326.44M | -29.05M | 950,000 | -2.05M | -42.80M | -2.03M | -731,000 |
| Financing Activities | ||||||||||
| Long-Term Debt Issuance | — | — | — | 15.02M | — | — | — | — | — | — |
| Long-Term Debt Payments | -5.00M | -1.07M | -11,000 | — | — | — | — | — | — | — |
| Other Financing Charges | -15.00M | -1.77M | 10,000 | -62,000 | -21,000 | — | -801,000 | -1.25M | 3.50M | 4.00M |
| Financing Cash Flow | -52.05M | -79.31M | 85.32M | 276.10M | 28.72M | — | -801,000 | 45.79M | 3.50M | 4.00M |
| Other Cash Details | ||||||||||
| End Cash Position | 97.47M | 79.51M | 164.89M | 87.43M | 11.97M | 6.74M | 6.49M | 7.90M | 498,000 | 172,000 |
| Income Tax Paid | 3.26M | 56.19M | 237.07M | 20.61M | 20,000 | 1,000 | 757,000 | 550,000 | — | — |
| Interest Paid | 960,000 | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 4.80M | 224.75M | 514.73M | 105.50M | 4.34M | -3.51M | -4.03M | 617,000 | -3.07M | -5.13M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 1,307,255 | 22.01M | 4.27% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 604,635 | 10.18M | 1.98% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 569,142 | 9.58M | 1.86% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 331,954 | 5.59M | 1.09% |
| Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | Oct 31, 2024 | 264,689 | 4.46M | 0.87% |
| DFA U.S. Targeted Value Portfolio | Oct 31, 2024 | 210,529 | 3.55M | 0.69% |
| iShares S&P Smallcap 600 Value ETF | Nov 30, 2024 | 205,133 | 3.45M | 0.67% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 201,395 | 3.39M | 0.66% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 200,089 | 3.37M | 0.65% |
| Northern Lights Fd Tr II-Invenomic Fd | Oct 31, 2024 | 194,590 | 3.28M | 0.64% |
Article
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the result.
Feb 6, 2025
Article
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.
Feb 4, 2025
Article
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Dec 24, 2024
